Sale of fluoroquinolones in northern Tanzania: A potential threat for fluoroquinolone use in tuberculosis treatment

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 1, 2009, Pages 145-147

  van den Boogaard, Jossy ^a,b   Semvua, Hadija H ^b   Boeree, Martin J ^a   Aarnoutse, Rob E ^a   Kibiki, Gibson S ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

Author keywords

Antibacterials; Defined daily dose methodology; Resistance

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG UTILIZATION; HUMAN; PRESCRIPTION; TANZANIA; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 77950362075     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp413     Document Type: Article

References (10)

1. Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002; 65: 455-64.
2. Van den Boogaard J, Kibiki GS, Kisanga ER et al. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009; 53: 849-62.
3. World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. WHO/HTM/TB/2006.361. Geneva: WHO, 2006.
4. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis; 2003; 3: 432-42.
5. Ferech M, Coenen S, Malhotra-Kumar S et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. J Antimicrob Chemother 2006; 58: 423-7.
6. Goossens H, Ferech M, Coenen S et al. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin Infect Dis 2007; 44: 1091-5.
7. World Health Organization. Global Tuberculosis Control 2009: Epidemiology, Strategy, Financing. WHO/HTM/TB/2009.411. Geneva: WHO, 2009.
8. Strategies for Enhancing Access to Medicines Program. Access to Essential Medicines: Tanzania, 2001. Arlington, VA: Management Sciences for Health, 2003.
9. WHO Collaborating Centre for Drug Statistics Methodology. The ATC/DDD System. http://www.whocc.no/atcddd (3 August 2009, date last accessed).
10. Ferech M, Coenen S, Malhotra-Kumar S et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother 2006; 58: 401-7.